Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505633 | 0.84 | JAK2 (0.49) | JAK2JAK1TYK2MAPK1 | |
| SCHEMBL15059666 | 0.78 | JAK2 (0.45) | JAK2JAK1TYK2 | |
| SCHEMBL2550838 | 0.76 | MAPK1 (0.47) | JAK2JAK1TYK2MAPK1 | |
| SCHEMBL12815681 | 0.76 | MAPK1 (0.46) | JAK2JAK1TYK2MAPK1 | |
| SCHEMBL2547775 | 0.76 | MAPK1 (0.47) | JAK2JAK1TYK2MAPK1 | |
| SCHEMBL12821859 | 0.76 | MAPK1 (0.46) | JAK2JAK1TYK2MAPK1 | |
| SCHEMBL12815117 | 0.75 | MAPK1 (0.45) | JAK2JAK1TYK2MAPK1 | |
| SCHEMBL17143267 | 0.75 | PTK2 (0.50) | JAK2JAK1TYK2 | |
| SCHEMBL16204330 | 0.75 | — | — | |
| SCHEMBL12815499 | 0.74 | MAPK1 (0.46) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9060515-B2 | Heterocyclic urea compounds | BIOTA EUROPE LTD. (GB) | 2015-06-23 | — | — | US | disclosed |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | SPERO GYRASE, INC. | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | UMPS, URB2, UROD | JAK2 4402/4885JAK1 4485/4885TYK2 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.